TNF-alpha Level, a Marker for Ivermectin Induced Immune Modulation in Cattle with Ocular Squamous Cell Carcinoma (BOSCC)

Ivermectin drug used in the treatment of endo and ecto parasites in animals, but in this study was used to treat Bovine ocularsquamous cell carcinoma (BOSCC) at a dose 200 mg /Kg body weight. Forty cattle were used in this study in a period from January 2014 to December 2015. The result of this study was revealed significant increase (P≤0.05) in the mean of total white blood cells count (5.39 ± 1.052) cell/mm3 before treatment and reach to (6.49 ± 0.422)cell/mm3 after treatment and the mean of lymphocyte rate (34.5 ± 3.20)% before treatment and reach to (60.6±10.83)% after treatment. Also, there was significant depression (P≤0.05) in the means of neutrophils and monocytes rates (59.4 ±4.52)% , (4.3 ±1.40)% before treatment compare with percentage of cells after treatment were (34.4 ±9.56)% , (2.2 ± 1.15)% respectively. The result showed significant (P≤0.05) decreased in the TNF-Alpha level (10.1 ± 1.1) ng/L in after treatment, while was (14.9 ± 0.48) ng/L before treatment compare with the control group was (6.5 ± 3.1) ng/L. Sixteen cattle were recovering from sum of twenty cattle in the treated group, the cure rate reaches to 80% with sign of loss the cancer mass size without any side effect on the animals. The Ivermectin could be a drug to treat BOSCC with a 80% cure rate.